Serious adverse events · postmenopausal women at lower risk of fractures1
It is very uncertain whether risedronate 5 mg/day changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
RR 0.74 [0.42, 1.3]
Studies not reported
Very low
All‐cause mortality · people hospitalised with COVID‐19
Higher‐dose anticoagulants showed no clear difference in all‐cause mortality compared with lower‐dose anticoagulants (high certainty).
1 finding from 1 review
Necessity for additional respiratory support · people hospitalised with COVID‐19
It is very uncertain whether higher‐dose anticoagulants changes necessity for additional respiratory support compared with lower‐dose anticoagulants (very low certainty).
1 finding from 1 review
Mortality related to COVID‐19 · people hospitalised with COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Deep vein thrombosis · people hospitalised with COVID‐19
Higher‐dose anticoagulants showed no clear difference in deep vein thrombosis compared with lower‐dose anticoagulants (low certainty).
1 finding from 1 review
Pulmonary embolism · people hospitalised with COVID‐19
Higher‐dose anticoagulants probably leads to lower pulmonary embolism compared with lower‐dose anticoagulants (moderate certainty).
1 finding from 1 review
Major bleeding · people hospitalised with COVID‐19
Higher‐dose anticoagulants probably leads to higher major bleeding compared with lower‐dose anticoagulants (moderate certainty).
1 finding from 1 review
Adverse events (minor bleeding) · people hospitalised with COVID‐19
Higher‐dose anticoagulants leads to higher adverse events (minor bleeding) compared with lower‐dose anticoagulants (high certainty).
1 finding from 1 review
30‐Day amputation‐free survival · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Amputation · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
30‐Day mortality · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Vessel patency (up to 30 days) · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Duration of thrombolysis (to end of treatment) · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Stroke · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Major bleeding · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Intervention not reported
30‐Day amputation‐free survival · patients with less than 42 days' lower limb ischaemia
1 finding from 1 review
Intervention not reported
Amputation ( · patients with less than 42 days' lower limb ischaemia
1 finding from 1 review
Intervention not reported
30‐Day mortality · patients with less than 42 days' lower limb ischaemia
1 finding from 1 review
Intervention not reported
Vessel patency ( · patients with less than 42 days' lower limb ischaemia
It is very uncertain whether the intervention changes vessel patency ( (very low certainty).
1 finding from 1 review
Intervention not reported
Duration of thrombolysis ( · patients with less than 42 days' lower limb ischaemia
1 finding from 1 review